

TEVA PHARMACEUTICAL INDUSTRIES LTD  
Form 425  
July 22, 2008

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16**

**under the Securities Exchange Act of 1934**

For the month of July 2008

Commission File Number 0-16174

**TEVA PHARMACEUTICAL INDUSTRIES LIMITED**

(Translation of registrant's name into English)

**5 Basel Street, P.O. Box 3190**

**Petach Tikva 49131 Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  X       Form 40-F \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also hereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes \_\_\_\_\_      No  X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g(3)-2(b): 82-

On July 18, 2008, Teva Pharmaceutical Industries Limited. ( Teva ) and Barr Pharmaceuticals, Inc. ( Barr ) hosted a teleconference wherein members of the respective management teams of Teva and Barr announced and discussed their entry into a definitive Agreement and Plan of Merger (the Merger Agreement ) and provided the participants of the teleconference an opportunity to ask questions regarding the transaction and Merger Agreement. A copy of the transcript of the teleconference is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In connection with the proposed transaction, Teva intends to file a registration statement and other materials with the Securities and Exchange Commission (the SEC ). Investors are urged to read the registration statement and other materials when they are available because they will contain important information. Investors will be able to obtain free copies of the registration statement, when they become available, as well as other filings containing information about Teva, at the SEC s Internet site (<http://www.sec.gov>). These documents also may be obtained free of charge by directing a request to Teva Investor Relations c/o Dorit Meltzer at P.O. Box 3190, Petah Tiqva 49131, Israel, 972-3-926-7554.

#### **Financial Statements and Exhibits**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Transcript of teleconference held July 18, 2008, hosted by Teva Pharmaceutical Industries Limited and Barr Pharmaceuticals, Inc.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Registrant)

By: /s/ Eyal Desheh  
Name: Eyal Desheh

Title: Chief Financial Officer

Date: July 22, 2008